[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343107-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343107-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","schlafen-11-further-sensitizes-brca-deficient-cells-to-parp-inhibitors-through-single-strand-dna-gap-accumulation-behind-replication-forks","Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks","","Preferential PARP inhibitor (PARPi) responses in BRCA-deﬁcient and Schlafen 11 (SLFN11)-expressing ovarian cancers are observed, but the molecular basis is unclear. The study examines how SLFN11 expression and BRCA deficiency jointly shape PARPi sensitivity and single-strand DNA (ssDNA) gap formation. PARPis increase chromatin-bound RPA2 and ssDNA gaps in SLFN11-expressing cells, especially with BRCA1 or BRCA2 loss, with SLFN11 colocalizing to RPA2. Recruitment depends on MRE11 activity, and clinical responders to olaparib show higher SLFN11 positivity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/schlafen-11-further-sensitizes-brca-deficient-cells-to-parp-inhibitors-through-single-strand-dna-gap-accumulation-behind-replication-forks/343107/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/schlafen-11-further-sensitizes-brca-deficient-cells-to-parp-inhibitors-through-single-strand-dna-gap-accumulation-behind-replication-forks/343107.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What key cellular change is linked to PARPi lethality in this study?","Question",{"text":63,"@type":64},"Accumulation of single-strand DNA (ssDNA) gaps behind replication forks, which correlates with increased chromatin-bound RPA2 and toxic DNA damage when PARP is inhibited.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do SLFN11 expression and BRCA loss affect PARPi sensitivity?",{"text":68,"@type":64},"PARPis raise ssDNA gaps and chromatin-bound RPA2 in SLFN11-expressing cells, with a stronger effect when BRCA1 or BRCA2 is deficient, indicating a combined sensitizing role.",{"name":70,"@type":61,"acceptedAnswer":71},"What determines SLFN11 recruitment during PARPi treatment?",{"text":72,"@type":64},"SLFN11 recruitment is attenuated by inactivation of MRE11, implying that MRE11-dependent processes facilitate SLFN11 binding to chromatin under PARPi exposure.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343107,1790153500,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nSchlafen 11 further sensitizes BRCA-deﬁcient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks  \nHiroshi Onji 1,2, Sota Tate 2,3, Tomohisa Sakaue3,4, Kohei Fujiwara5,6, Shiho Nakano1,2, Miho Kawaida7, Nobuyuki Onishi8,9, Takashi Matsumoto1, Wataru Yamagami 10, Takashi Sugiyama 1, Shigeki Higashiyama2,3,11, Yves Pommier12, Yusuke Kobayashi 10,13 ✉ and Junko Murai 2,3,14 ✉  \n© The Author(s) 2024  \n\n| | The preferential response to PARP inhibitors (PARPis) in BRCA-deﬁcient and Schlafen 11 (SLFN11)-expressing ovarian cancers has been documented, yet the underlying molecular mechanisms remain unclear. As the accumulation of single-strand DNA (ssDNA) gaps behind replication forks is key for the lethality effect of PARPis, we investigated the combined effects of SLFN11 expression and BRCA deﬁciency on PARPi sensitivity and ssDNA gap formation in human cancer cells. PARPis increased chromatin-bound RPA2 and ssDNA gaps in SLFN11-expressing cells and even more in cells with BRCA1 or BRCA2 deﬁciency. SLFN11 was co-localized with chromatin-bound RPA2 under PARPis treatment, with enhanced recruitment in BRCA2-deﬁcient cells. Notably, the chromatinbound SLFN11 under PARPis did not block replication, contrary to its function under replication stress. SLFN11 recruitment was attenuated by the inactivation of MRE11 . Hence, under PARPi treatment, MRE11 expression and BRCA deﬁciency lead to ssDNA gaps behind replication forks, where SLFN11 binds and increases their accumulation. As ovarian cancer patients who responded (progression-free survival >2 years) to olaparib maintenance therapy had a signiﬁcantly higher SLFN11-positivity than shortresponders (\u003C6 months), our ﬁndings provide a mechanistic understanding of the favorable responses to PARPis in SLFN11-expressing and BRCA-deﬁcient tumors. It highlight the clinical implications of SLFN11 .\u003Cbr>Oncogene (2024) 43:2475–2489; [https://doi.org/10.1038/s41388-024-03094-1](https://doi.org/10.1038/s41388-024-03094-1) | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n\nGraphical Abstract  \n : DNA polymerase  \n : DNA helicase  \n : RPA complex  \n: SLFN11  \n : PARP inhibitor  \n : (trapped) PARP1  \n: MRE11  \nINTRODUCTION  \nPoly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) were the ﬁrst drugs to highlight the concept of synthetic lethality in clinical  \noncology [1] . Initial models proposed that catalytic PARPis prevent the repair of single-strand DNA (ssDNA) breaks that are subsequently converted into double-strand DNA breaks (DSBs) upon  \n1Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. 2Department of Biochemistry and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. 3Division of Cell Growth and Tumor Regulation, Proteo-Science Center (PROS), Toon, Ehime, Japan. 4Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. 5Division of Physiological Chemistry and Metabolism, Graduate School of Pharmaceutical Sciences, Keio University, Minato-ku, Tokyo, Japan. 6Laboratory for Metabolomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan. 7Division of Diagnostic Pathology, Keio University Hospital, Shinjuku-ku, Tokyo, Japan. 8Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Shinagawa-ku, Tokyo, Japan. 9Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. 10Department of Obstetrics and Gynecology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan. 11Department of Oncogenesis and Tumor Regulation, Osaka International Cancer Institute, Chuo-ku, Osaka, J","cbCaikBPm17BoqZQ","https://ap.wps.com/l/cbCaikBPm17BoqZQ","pdf",3905793,15,"English","# Introduction\n## Synthetic lethality and PARPi mechanisms (PARylation inhibition, PARP trapping)\n## Rationale for combining SLFN11 expression with BRCA deficiency\n## Replication-fork ssDNA gaps and mechanistic hypotheses","[{\"question\":\"What key cellular change is linked to PARPi lethality in this study?\",\"answer\":\"Accumulation of single-strand DNA (ssDNA) gaps behind replication forks, which correlates with increased chromatin-bound RPA2 and toxic DNA damage when PARP is inhibited.\"},{\"question\":\"How do SLFN11 expression and BRCA loss affect PARPi sensitivity?\",\"answer\":\"PARPis raise ssDNA gaps and chromatin-bound RPA2 in SLFN11-expressing cells, with a stronger effect when BRCA1 or BRCA2 is deficient, indicating a combined sensitizing role.\"},{\"question\":\"What determines SLFN11 recruitment during PARPi treatment?\",\"answer\":\"SLFN11 recruitment is attenuated by inactivation of MRE11, implying that MRE11-dependent processes facilitate SLFN11 binding to chromatin under PARPi exposure.\"}]","Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks | PDF",1790049928,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/582c29b4022426b0139201207614c427.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/051be7ac1a8c43102fc0a99d58a10e81.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cb3803ba68a9e8cf302f20b9e907c40.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2421b4316cb1f5a91c75488bf61d009.webp",980,1301]